Press release
Anti-CD20 Monoclonal Antibodies Market to Record 7.6% CAGR Growth Through 2029 | Global Analysis Report
Anti CD20 Monoclonal Antibodies
Anti-CD20 Monoclonal Antibodies Market Outlook: How is the Market Expected to Grow by 2025?
The market for anti-CD20 monoclonal antibodies has experienced substantial growth recently. Its size is projected to increase from $8.33 billion in 2024 to $9.00 billion in 2025, representing a compound annual growth rate (CAGR) of 7.9%. The growth seen historically can be linked to the rising occurrence of B-cell malignancies, wider uptake in treating autoimmune diseases, more FDA and EMA approvals for novel anti-CD20 therapies, and the expanding global elderly population.
Anti-CD20 Monoclonal Antibodies Market Forecast: What Size Will It Reach By 2029?
The market for anti-CD20 monoclonal antibodies is set to witness substantial expansion in the coming years, soaring to a value of $12.05 billion by 2029 at a compound annual growth rate (CAGR) of 7.6%. This anticipated growth over the forecast duration can be accredited to factors such as increasing strategic partnerships and licensing contracts, the widened use in combined treatment plans, the escalating numbers of relapsed or refractory cases, growing healthcare spending and accessibility in emerging markets, and the rise in biosimilar development and approvals. The forecast period will also see key trends such as the evolution in monoclonal antibody engineering, the incorporation of anti-CD20 antibodies in combination treatments, the advancement of technology-led personalized cancer treatments, progress in subcutaneous and prolonged-release formulations, and improvements in bispecific and cutting-edge antibodies.
Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report
Which Key Market Drivers Will Shape Anti-CD20 Monoclonal Antibodies Industry Trends in 2025-2029?
The anti-CD20 monoclonal antibodies market is predicted to expand due to the increasing prevalence of autoimmune diseases. These disorders arise when the immune system mistakenly targets the body's cells as harmful and attacks them. Increased exposure to environmental pollutants, which can disrupt immune regulation and initiate attacks on the body's tissues, is leading to a rise in autoimmune diseases. Anti-CD20 monoclonal antibodies alleviate symptoms of autoimmune diseases by eradicating B cells that assist in producing autoantibodies and inflammation. These antibodies help in controlling the immune response and diminishing disease symptoms. For instance, the Australian Institute of Health and Welfare, a government organization based in Australia, reported in June 2024 that about 514,000 individuals (2.0%) were living with rheumatoid arthritis, a systemic autoimmune disorder, in Australia in 2022, with 2.5% females and 1.6% males affected. Consequently, the rising incidences of autoimmune diseases are fueling the growth of the anti-CD20 monoclonal antibodies market.
Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp
What Are the High-Growth Segments in the Anti-CD20 Monoclonal Antibodies Market?
The anti-cd20 monoclonal antibodies market covered in this report is segmented -
1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications
5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users
Subsegments:
1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux
2) By Obinutuzumab: Gazyva, Biosimilar Candidates
3) By Ofatumumab: Arzerra, Kesimpta
4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab
Which Global Trends Are Driving Anti-CD20 Monoclonal Antibodies Market Expansion?
Key players in the anti-CD20 monoclonal antibody market are directing their efforts towards developing superior products like obinutuzumab to more effectively target stubborn or recurrent B-cell malignancies. Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is specifically designed to identify and eliminate CD20-positive B cells that play a role in certain blood cancers and autoimmune disorders. Case in point, in March 2025, the US Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) from Roche, a biopharmaceutical industry leader based in Switzerland, for lupus nephritis treatment. This approval was fueled by positive outcomes from the Phase III REGENCY trial which demonstrated enhanced complete renal response (CRR) when administered in tandem with standard treatment compared to the standard treatment alone. This places Gazyva/Gazyvaro in a unique position, being the sole anti-CD20 monoclonal antibody demonstrated to offer such advantage in treating lupus nephritis, a serious inflammatory condition triggered by lupus potentially leading to kidney failure.
Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp
Who Are the Fastest-Growing Companies in the Anti-CD20 Monoclonal Antibodies Industry?
Major companies operating in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH
What Is the Regional Outlook for the Anti-CD20 Monoclonal Antibodies Market by 2029?
North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
#Reach Out to Us#
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-CD20 Monoclonal Antibodies Market to Record 7.6% CAGR Growth Through 2029 | Global Analysis Report here
News-ID: 4156364 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Anti
Black garlic might possess anti-cancer and anti-inflammatory benefits
The Wisconsin Fermentation Company is excited to announce groundbreaking
research highlighting the significant health benefits of black garlic. Known for its
unique flavor and texture, black garlic has long been valued in culinary traditions
across the world. Recent studies now suggest that this fermented delicacy may
possess potent anti-cancer and anti-inflammatory properties.
Research Highlights
Emerging research conducted by our team at the Wisconsin Fermentation Company,
in collaboration with leading health experts, indicates that black garlic could be…
Nanopharmaceuticals Market By Application ( Anti-infective, Anti-inflammatory, C …
Nanopharmaceuticals is an upcoming part of nanomedicine, which includes discovery/development and delivery of drugs using nanobiotechnology. It also includes the use of nanoparticles as therapeutic agents in various medical fields such as oncology, neurology, infectious diseases and others. nanopharmaceuticals are known to have different chemical, physical and biological properties as compared to their lager counterparts.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00003418/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
• Abbott
• GlaxoSmithKline plc.
• Stryker
• Kadmon Holdings, Inc.
•…
Sleeplab Anti-Snore Reviews: Best Anti Snore Chin Strap?
if you and your partner share the same bed, snoring can be a bad habit. People who snore don't know how annoying it is to others who are around them. If you want to get rid of this, you need a gadget that can massage your throat and stop you from snoring at the same time.
Almost half of adults snore while asleep. People who are overweight are more likely to…
Anti-Venom Market Report 2018: Segmentation by Anti-Venom Type (Monovalent, Poly …
Global Anti-Venom market research report provides company profile for CSL Behring, Bharat Serums and Vaccines Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd, Vacsera, Vins Bioproducts Limited, Rare Therapeutics and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,…
Anti-Suicide Drugs Market Report 2018: Segmentation by Chemistry Type (Anti-Depr …
Global Anti-Suicide Drugs market research report provides company profile for Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., Johnson & Johnson and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate,…
Top Leading Vendors of “Anti-Aging Products and Services Market” by product …
Axiom Market Research & Consulting added a latest report on ‘Global Anti-aging Products and Services Market, By Services, Devices, Products, Demographics, End Users and Geography – Global Market Share, Trend Analysis & Forecast Up To 2024’ The global anti-aging products and services market is anticipated to develop at a CAGR of 4.23% from 2019 to 2024.
The market is revised for its services, such as anti-pigmentation therapy, adult acne therapy,…
